Overview
Zymeworks Q2 2025 revenue rises to $48.7 mln, driven by milestone payments
Net income for Q2 2025 reaches $2.3 mln, reversing last year's loss
FDA clears IND for ZW251, first-in-human studies planned for 2025
Outlook
Company expects cash resources to fund operations into 2H-2027
Result Drivers
MILESTONE PAYMENTS - $20 mln milestone from BeOne for zanidatamab approval in China and $7.5 mln from BMS commercial license option
PARTNERSHIP REVENUE - Revenue driven by strategic partnerships and collaborations, including Jazz and J&J
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Net Income | $2.32 mln | ||
Q2 Income From Operations | -$674,000 | ||
Q2 Operating Expenses | $49.40 mln | ||
Q2 Pretax Profit | $2.13 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Zymeworks Inc is $19.50, about 36.4% above its August 6 closing price of $12.41
Press Release: ID:nGNXtVNdB
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。